Oak Associates’s Moderna MRNA Stock Holding History

Oak Associates’s Portfolio MRNA Stock Details MRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-13,898	Closed	-$1.44M	–	137
2023 Q3	$1.44M	Buy	13,898 +817	+6%	+$91.1K	0.12%	89
2023 Q2	$1.59M	Hold	13,081	–	–	0.13%	88
2023 Q1	$2.01M	Hold	13,081	–	–	0.17%	80
2022 Q4	$2.35M	Buy	13,081 +490	+4%	+$80.1K	0.2%	80
2022 Q3	$1.49M	Buy	12,591 +3,198	+34%	+$485K	0.13%	89
2022 Q2	$1.34M	Buy	+9,393	New	+$1.34M	0.1%	88

Other funds holding MRNA

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Oak Associates's MRNA Position: Q4 2023 in Review

Oak Associates sold out of Moderna (MRNA) in Q4 2023, closing a stake of 13,898 shares — an estimated $1.44M sold.

Oak Associates first reported a position in MRNA in Q2 2022 and held it in 6 quarters. The position peaked at $2.35M in Q4 2022. 884 funds tracked by Wall St. Rank hold MRNA as of Q4 2023.

Oak Associates reported no remaining Moderna position as of Q4 2023 after selling out during the quarter.
Oak Associates sold 13,898 Moderna shares in Q4 2023, an estimated $1.44M.
Oak Associates first reported a position in Moderna in Q2 2022 and held it in 6 quarters.
Oak Associates's Moderna position peaked at $2.35M in Q4 2022.
884 funds tracked by Wall St. Rank held Moderna as of Q4 2023.

Based on Oak Associates's 13F filing for Q4 2023, filed 14 Feb 2024.